Out-of-Pocket Healthcare Spending

Price Transparency Healthcare Policies Reduce Out-Of-Pocket Costs

December 11, 2023 - Price transparency enables patients to shop for the most effective and inexpensive healthcare available and is vital as patient out-of-pocket healthcare costs continue to skyrocket year-over-year.   A 2021 Kalorama Information analysis found that patient out-of-pocket costs are up 10% since 2020, with the net total of patient financial responsibility nearly $491 billion in 2021....

Read More


More Articles

Majority of Patients Quit Weight-Loss Drugs Like Wegovy Within First Year

by Hayden Schmidt

A recent cost analysis shared with Reuters showed that only a third of patients continued to use popular glucagon-like peptide-1 (GLP-1) compounds a year after initial prescription. Healthcare costs...

Top Challenges Facing Biosimilar Adoption and Manufacturing

by Veronica Salib

Biosimilar adoption by the healthcare industry can incentivize pharmaceutical development and increase options for patients, payers, and providers by offering a less expensive alternative to biologic...

Prescription Drug Manufacturer Pre-Rebate Costs Skyrocket

by Samantha McGrail

From 2015 to 2019, median prescription drug manufacturer pre-rebate costs per covered life (PCL) increased by 68.1% for individual plans, 44.9% for small group plans, and 23.9% for large group plans,...

Pharma Companies Challenge Federal Plans to Lower Drug Pricing

by Samantha McGrail

PhRMA member companies encourage Congress to abandon old partisan ideas on drug pricing and pursue policies that address patients out of pocket costs, according to a new official letter.  The...

Pharmaceutical Supply Chain Needs Reform for Transparency, Access

by Samantha McGrail

The US pharmaceutical supply chain must be remodeled to address long-standing conflicts and achieve a delivery model marked by transparency, affordability, and access to care, according to an expert...

Out-of-Pocket Costs for Brand-Name Medications Increased 15%

by Samantha McGrail

JAMA Network Open study found that change in brand-name medication prices for most commercially insured patients correlated with changes in out-of-pocket costs. In the study, nearly 53.7 percent of...

Supreme Court Allows States to Regulate Pharmacy Benefit Managers

by Samantha McGrail

The Supreme Court unanimously ruled that US states can regulate pharmacy benefit managers.  The decision released at the beginning of December ruled in favor of groups arguing on behalf of...

Walmart Acquires Pharmacy Management Capabilities from CareZone

by Samantha McGrail

Walmart recently announced that it acquired specific assets of CareZone, a pharmacy management app that allows patients and families to manage medications as well as physician...

Sanofi to Pay $11.85M to Resolve Medicare Fraud Allegations

by Samantha McGrail

The US Justice Department announced that pharmaceutical company Sanofi SA agreed to pay $11.85 million to resolve Medicare fraud accusations involving a recent charity kickback probe.  Sanofi...

Policymakers Call Out Express Scripts Over Rising Insulin Prices

by Samantha McGrail

Two members of the United States Committee on Finance made a final document request to pharmacy benefit manager Express Scripts, owned by Cigna, and warned that failure to comply will result in a...

Prescription Drug Prices Rose 21% as Utilization Remained Steady

by Samantha McGrail

Prescription drug prices continue to increase due to continued growth in medical service costs and a modest uptick in utilization, according to a recent report from the Health Care Cost Institute...

Recent Articles